NCT05567835 2026-04-09
TOGAR
Baylor College of Medicine
Phase 2 Terminated
Clinical Trials
283 trialsNCT02997332 2026-03-23
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT06038539 2026-03-13
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Biocon Limited
Phase 3 Terminated
NCT05381909 2026-02-20
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT04037527 2026-02-04
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Wake Forest University Health Sciences
Phase 1 Terminated
NCT04095689 2026-01-23
INTEGRAL
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT04396535 2025-11-17
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Terminated
NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01382706 2025-10-09
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Phase 2 Terminated
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04921358 2025-06-29
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT05461794 2025-06-13
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
BeiGene
Phase 2 Terminated
NCT03442556 2025-06-12
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
Phase 2 Terminated
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated
NCT04827576 2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2 Terminated
NCT00253318 2025-04-27
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT05267470 2025-03-25
FORTITUDE-201
Amgen
Phase 1 Terminated
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT05062980 2025-02-20
Acclaim-2
Genprex, Inc.
Phase 1/2 Terminated
NCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT03854227 2025-01-13
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT01705483 2024-11-07
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
Astellas Pharma Inc
Phase 1 Terminated
NCT04937738 2024-11-06
PECORINO
Ukrainian Society of Clinical Oncology
Phase 2 Terminated
NCT05156905 2024-10-09
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
University of California, San Diego
Phase 1 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT04583488 2024-08-09
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Johns Hopkins University
Phase 1 Terminated
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT03435250 2024-07-25
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Servier
Phase 1 Terminated
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03393741 2024-06-25
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
Terminated
NCT03095612 2024-06-13
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03066154 2024-06-03
DOP
The Netherlands Cancer Institute
Phase 1 Terminated
NCT05207514 2024-05-17
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT05148195 2024-03-13
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT04171284 2024-02-09
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Sinocelltech Ltd.
Phase 3 Terminated
NCT02654587 2024-02-02
ATALANTE-1
OSE Immunotherapeutics
Phase 3 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT00176631 2023-12-22
Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT03837353 2023-12-18
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
NYU Langone Health
Phase 1/2 Terminated
NCT03228186 2023-10-23
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT04404140 2023-10-17
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hoffmann-La Roche
Phase 1 Terminated
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated